Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial.

Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, Heron B, Geraci S, Ardigò D, Cattaneo F, Fogh J, Van den Hout JMH, Beck M, Jones SA, Tylki-Szymanska A, Haugsted U, Lund AM.

J Inherit Metab Dis. 2018 May 30. doi: 10.1007/s10545-018-0185-0. [Epub ahead of print]

PMID:
29846843
2.

Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.

Lund AM, Borgwardt L, Cattaneo F, Ardigò D, Geraci S, Gil-Campos M, De Meirleir L, Laroche C, Dolhem P, Cole D, Tylki-Szymanska A, Lopez-Rodriguez M, Guillén-Navarro E, Dali CI, Héron B, Fogh J, Muschol N, Phillips D, Van den Hout JMH, Jones SA, Amraoui Y, Harmatz P, Guffon N.

J Inherit Metab Dis. 2018 May 3. doi: 10.1007/s10545-018-0175-2. [Epub ahead of print]

PMID:
29725868
3.

Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice.

Stroobants S, Damme M, Van der Jeugd A, Vermaercke B, Andersson C, Fogh J, Saftig P, Blanz J, D'Hooge R.

Neurobiol Dis. 2017 Oct;106:255-268. doi: 10.1016/j.nbd.2017.07.013. Epub 2017 Jul 15.

PMID:
28720484
4.

Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.

Damme M, Stroobants S, Lüdemann M, Rothaug M, Lüllmann-Rauch R, Beck HC, Ericsson A, Andersson C, Fogh J, D'Hooge R, Saftig P, Blanz J.

Ann Clin Transl Neurol. 2015 Sep 19;2(11):987-1001. doi: 10.1002/acn3.245. eCollection 2015 Nov.

5.

Alpha-mannosidosis: characterization of CNS pathology and correlation between CNS pathology and cognitive function.

Borgwardt L, Danielsen ER, Thomsen C, Månsson JE, Taouatas N, Thuesen AM, Olsen KJ, Fogh J, Dali CI, Lund AM.

Clin Genet. 2016 Apr;89(4):489-494. doi: 10.1111/cge.12642. Epub 2015 Sep 4.

PMID:
26212233
6.

Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation.

Borgwardt L, Stensland HM, Olsen KJ, Wibrand F, Klenow HB, Beck M, Amraoui Y, Arash L, Fogh J, Nilssen Ø, Dali CI, Lund AM.

Orphanet J Rare Dis. 2015 Jun 6;10:70. doi: 10.1186/s13023-015-0286-x.

7.

Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis.

Borgwardt L, Thuesen AM, Olsen KJ, Fogh J, Dali CI, Lund AM.

J Inherit Metab Dis. 2015 Nov;38(6):1119-27. doi: 10.1007/s10545-015-9862-4. Epub 2015 May 28.

PMID:
26016802
8.

Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy.

Matthes F, Andersson C, Stein A, Eistrup C, Fogh J, Gieselmann V, Wenger DA, Matzner U.

Exp Neurol. 2015 Sep;271:36-45. doi: 10.1016/j.expneurol.2015.04.020. Epub 2015 May 6.

PMID:
25956830
9.

Thermal degradation and stability of sodium hyaluronate in solid state.

Caspersen MB, Roubroeks JP, Qun L, Shan H, Fogh J, Ruidong Z, Tømmeraas K.

Carbohydr Polym. 2014 Jul 17;107:25-30. doi: 10.1016/j.carbpol.2014.02.005. Epub 2014 Feb 15.

PMID:
24702914
10.

Natural history of alpha mannosidosis a longitudinal study.

Beck M, Olsen KJ, Wraith JE, Zeman J, Michalski JC, Saftig P, Fogh J, Malm D.

Orphanet J Rare Dis. 2013 Jun 20;8:88. doi: 10.1186/1750-1172-8-88.

11.

Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study.

Borgwardt L, Dali CI, Fogh J, Månsson JE, Olsen KJ, Beck HC, Nielsen KG, Nielsen LH, Olsen SO, Riise Stensland HM, Nilssen O, Wibrand F, Thuesen AM, Pearl T, Haugsted U, Saftig P, Blanz J, Jones SA, Tylki-Szymanska A, Guffon-Fouiloux N, Beck M, Lund AM.

J Inherit Metab Dis. 2013 Nov;36(6):1015-24. doi: 10.1007/s10545-013-9595-1. Epub 2013 Mar 14.

PMID:
23494656
12.

Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age.

Matthes F, Stroobants S, Gerlach D, Wohlenberg C, Wessig C, Fogh J, Gieselmann V, Eckhardt M, D'Hooge R, Matzner U.

Hum Mol Genet. 2012 Jun 1;21(11):2599-609. doi: 10.1093/hmg/dds086. Epub 2012 Mar 2.

PMID:
22388935
13.

Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy.

Stroobants S, Gerlach D, Matthes F, Hartmann D, Fogh J, Gieselmann V, D'Hooge R, Matzner U.

Hum Mol Genet. 2011 Jul 15;20(14):2760-9. doi: 10.1093/hmg/ddr175. Epub 2011 Apr 22.

PMID:
21515587
14.

Transport of arylsulfatase A across the blood-brain barrier in vitro.

Matthes F, Wölte P, Böckenhoff A, Hüwel S, Schulz M, Hyden P, Fogh J, Gieselmann V, Galla HJ, Matzner U.

J Biol Chem. 2011 May 20;286(20):17487-94. doi: 10.1074/jbc.M110.189381. Epub 2011 Mar 28.

15.

Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis.

Damme M, Stroobants S, Walkley SU, Lüllmann-Rauch R, D'Hooge R, Fogh J, Saftig P, Lübke T, Blanz J.

J Neuropathol Exp Neurol. 2011 Jan;70(1):83-94. doi: 10.1097/NEN.0b013e31820428fa.

16.

Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy.

i Dali C, Hanson LG, Barton NW, Fogh J, Nair N, Lund AM.

Neurology. 2010 Nov 23;75(21):1896-903. doi: 10.1212/WNL.0b013e3181feb217.

PMID:
21098404
17.

Impaired lysosomal trimming of N-linked oligosaccharides leads to hyperglycosylation of native lysosomal proteins in mice with alpha-mannosidosis.

Damme M, Morelle W, Schmidt B, Andersson C, Fogh J, Michalski JC, Lübke T.

Mol Cell Biol. 2010 Jan;30(1):273-83. doi: 10.1128/MCB.01143-09.

18.

Site-specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines.

Schröder S, Matthes F, Hyden P, Andersson C, Fogh J, Müller-Loennies S, Braulke T, Gieselmann V, Matzner U.

Glycobiology. 2010 Feb;20(2):248-59. doi: 10.1093/glycob/cwp171. Epub 2009 Oct 28.

PMID:
19864504
19.

Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.

Matzner U, Lüllmann-Rauch R, Stroobants S, Andersson C, Weigelt C, Eistrup C, Fogh J, D'Hooge R, Gieselmann V.

Mol Ther. 2009 Apr;17(4):600-6. doi: 10.1038/mt.2008.305. Epub 2009 Jan 27.

20.

Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.

Blanz J, Stroobants S, Lüllmann-Rauch R, Morelle W, Lüdemann M, D'Hooge R, Reuterwall H, Michalski JC, Fogh J, Andersson C, Saftig P.

Hum Mol Genet. 2008 Nov 15;17(22):3437-45. doi: 10.1093/hmg/ddn237. Epub 2008 Aug 19.

PMID:
18713755
21.

Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease.

Matzner U, Matthes F, Weigelt C, Andersson C, Eistrup C, Fogh J, Gieselmann V.

J Mol Med (Berl). 2008 Apr;86(4):433-42. doi: 10.1007/s00109-008-0309-3. Epub 2008 Mar 18.

PMID:
18360747
22.

Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy.

Matzner U, Matthes F, Herbst E, Lüllmann-Rauch R, Callaerts-Vegh Z, D'Hooge R, Weigelt C, Eistrup C, Fogh J, Gieselmann V.

Mol Med. 2007 Sep-Oct;13(9-10):471-9.

23.

Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy.

Matzner U, Herbst E, Hedayati KK, Lüllmann-Rauch R, Wessig C, Schröder S, Eistrup C, Möller C, Fogh J, Gieselmann V.

Hum Mol Genet. 2005 May 1;14(9):1139-52. Epub 2005 Mar 16.

PMID:
15772092
24.

Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.

Roces DP, Lüllmann-Rauch R, Peng J, Balducci C, Andersson C, Tollersrud O, Fogh J, Orlacchio A, Beccari T, Saftig P, von Figura K.

Hum Mol Genet. 2004 Sep 15;13(18):1979-88. Epub 2004 Jul 21.

PMID:
15269179
26.
27.

Carcino-embryonic antigen in monitoring the growth of human colon adenocarcinoma tumour cells SK-CO-1 and HT-29 in vitro and in nude mice.

Sölétormos G, Fogh JM, Sehested-Hansen B, Spang-Thomsen M, Schiøler V, Dombernowsky P, Skovsgaard T.

Eur J Cancer. 1997 Jan;33(1):108-14.

PMID:
9071909
28.

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model.

Ottesen JL, Nilsson P, Jami J, Weilguny D, Dührkop M, Bucchini D, Havelund S, Fogh JM.

Diabetologia. 1994 Dec;37(12):1178-85.

PMID:
7895946
29.

Gene transfer into cultured human epidermis and its transplantation onto immunodeficient mice: an experimental model for somatic gene therapy.

Jensen UB, Jensen TG, Jensen PK, Rygaard J, Hansen BS, Fogh J, Kølvraa S, Bolund L.

J Invest Dermatol. 1994 Sep;103(3):391-4.

30.

Properties of the scrapie prion protein: quantitative analysis of protease resistance.

Oesch B, Jensen M, Nilsson P, Fogh J.

Biochemistry. 1994 May 17;33(19):5926-31.

PMID:
7910036
31.

[Bone scintigraphy in assessment of risk of complications after medial femoral neck fractures].

Lausten GS, Hesse B, Thygesen V, Fogh J.

Ugeskr Laeger. 1993 Jun 14;155(24):1864-7. Danish.

PMID:
8317045
32.

A specific assay for leukotriene B4 in human whole blood.

Fogh J, Poulsen LK, Bisgaard H.

J Pharmacol Toxicol Methods. 1992 Dec;28(4):185-90.

PMID:
1338371
33.

Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis.

Berning J, Rokkedal Nielsen J, Launbjerg J, Fogh J, Mickley H, Andersen PE.

Cardiology. 1992;80(3-4):257-66.

PMID:
1511472
34.

Prediction of late complications of femoral neck fractures by scintigraphy.

Lausten GS, Hesse B, Thygesen V, Fogh J.

Int Orthop. 1992;16(3):260-4.

PMID:
1428339
35.

Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.

Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H, Hansen M.

J Clin Oncol. 1990 Nov;8(11):1806-10.

PMID:
2230869
36.

Abnormal oesophageal function in patients with non-toxic goiter or enlarged left atrium, demonstrated by radionuclide transit measurements.

Jørgensen F, Hesse B, Grønbaek P, Fogh J, Haunsø S.

Scand J Gastroenterol. 1989 Dec;24(10):1186-92.

PMID:
2532392
37.

Reproducibility in the analysis of multigated radionuclide studies of left ventricular ejection fraction.

Gjørup T, Kelbaek H, Vestergaard B, Fogh J, Munck O, Jensen AM.

Invest Radiol. 1989 Feb;24(2):104-9.

PMID:
2917829
38.

Persistent impairment of liver function caused by a pendulated accessory liver lobe.

Fogh J, Tromholt N, Jørgensen F.

Eur J Nucl Med. 1989;15(6):326-7.

PMID:
2767082
39.

Reliability of scintigraphic diagnosis of liver metastases.

Gjørup T, Frederiksen PL, Fogh J, Conrad C, Olsen KJ, Nielsen SL, Munck O.

Scand J Gastroenterol. 1988 Oct;23(8):955-60.

PMID:
3201133
40.

[Scintigraphic follow-up control of pulmonary embolism].

Hvid-Jacobsen K, Fogh J, Nielsen SL, Thomsen HS, Dyrbye M.

Ugeskr Laeger. 1988 Jan 11;150(2):94-5. Danish. No abstract available.

PMID:
3376282
41.

Scintigraphic control of pulmonary embolism.

Hvid-Jacobsen K, Fogh J, Nielsen SL, Thomsen HS, Hartling OJ.

Eur J Nucl Med. 1988;14(2):71-2.

PMID:
3391214
42.

Inherited coagulation disorders.

Fogh JM, Fogh IT.

Vet Clin North Am Small Anim Pract. 1988 Jan;18(1):231-43. Review.

PMID:
3282382
43.

A study of hemophilia A in German shepherd dogs in Denmark.

Fogh JM.

Vet Clin North Am Small Anim Pract. 1988 Jan;18(1):245-54.

PMID:
3258687
44.

The predictive value of preoperative perfusion/ventilation scintigraphy, spirometry and x-ray of the lungs on postoperative pulmonary complications. A prospective study.

Fogh J, Willie-Jørgensen P, Brynjolf I, Thorup J, Jørgensen T, Bording L, Kjaergaard J.

Acta Anaesthesiol Scand. 1987 Nov;31(8):717-21.

PMID:
3501664
45.

In vivo stability of in vitro labelled 99Tcm-red blood cells for radionuclide determination of left ventricular ejection fractions and volumes.

Kelbaek H, Gjørup T, Fogh J.

Nucl Med Commun. 1986 Jul;7(7):541-7. Erratum in: Nucl Med Commun 1986 Dec;7(12):916.

PMID:
3774253
46.
47.

Interobserver variation in the detection of metastases on liver scans.

Gjørup T, Brahm M, Fogh J, Munck O, Jensen AM.

Gastroenterology. 1986 Jan;90(1):166-72.

PMID:
3940243
48.

Human tumor lines for cancer research.

Fogh J.

Cancer Invest. 1986;4(2):157-84. No abstract available.

PMID:
3518877
50.

Elaboration of granulocyte-macrophage colony-stimulating factor by human tumor cell lines and normal urothelium.

Zinzar SN, Svet-Moldavsky GJ, Fogh J, Mann PE, Arlin Z, Iliescu K, Holland JF.

Exp Hematol. 1985 Jul;13(6):574-80.

PMID:
3873349

Supplemental Content

Support Center